Advertisement

Tumor Biology

, Volume 36, Issue 1, pp 429–436 | Cite as

Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis

  • Mingfei Zhao
  • Hangdi Xu
  • Feng Liang
  • Jiliang He
  • Jianmin Zhang
Research Article

Abstract

So far, several studies on the association between osteopontin (OPN) expression and glioma have been performed, but the conclusion still was not clear. The aim of the present meta-analysis was to determine the relationship between OPN expression and prognosis of patients with glioma. The electronic database was searched for articles on the association between OPN expression and glioma until 31 January 2014. Odds ratios (OR) and the relative risks with 95 % CI were utilized to analyze the qualitative data in retrospective studies and prospective studies, respectively. The standardized mean difference and the corresponding 95 % CI were used for analyzing the studies with quantitative data. Heterogeneity of all included studies was assessed using Cochrane’s Q test and I 2 measurement. The publication bias was examined by the Egger test. Sixteen cohort studies (854 patients) on OPN expression and gliomas prognosis were included in the present meta-analysis. It was found that OPN expression was significantly higher in patients with high-grade glioma than in patients with low-grade glioma (χ 2 = 8.38, I 2  = 16.6 %, P = 0.300), and the expression of OPN increased with glioma grade. The combined data showed the correlation between high OPN expression and tumor reoccurrence (OR = 18.61, 95 % CI = 6.34–54.67, P = 0.405). In addition, the results of the pooled analysis indicated that OPN expression was significantly related to overall survival (HR = 1.83; 95 % CI = 1.36–2.46). In conclusion, OPN may be a biomarker for predicting the prognosis of gliomas.

Keywords

Osteopontin Glioma Prognosis Meta-analysis 

Notes

Acknowledgment

This work was supported by a grant from the National Natural Science Foundation of China (No. 81200956).

Conflicts of interest

None

Reference

  1. 1.
    Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 2010;19:1409–22.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsai WC, Lee HS, Lin CK, Chen A, Nieh S, Ma HI. The association of osteopontin and LMX1A expression with World Health Organization grade in meningiomas and gliomas. Histopathology. 2012;61:844–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007;67:2089–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Lu DY, Yeh WL, Huang SM, Tang CH, Lin HY, Chou SJ. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012;14:1367–78.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132:39–48.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol. 2014;48(9):806–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012;18:3923–30.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC. Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One. 2013;8:e69116.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ding Q, Stewart Jr J, Prince CW, Chang PL, Trikha M, Han X, et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 2002;62:5336–43.PubMedGoogle Scholar
  12. 12.
    He ZQ, Yin L, Zhao HY. Expression and significance of osteopontin and integrin β3 in human gliomas. CMINS. 2005;10:508–11.Google Scholar
  13. 13.
    Sun CY, Bu XY. Expression and significance of osteopontin in human gliomas. J Fourth Mil Med Univ. 2005;26:1677–9.Google Scholar
  14. 14.
    Yu WH, Chen F, Che ZH. Preliminary study on expression of osteopontin in human gliomas. J Med Res. 2006;35:17–9.Google Scholar
  15. 15.
    Cheng BC, Wan JH, Feng CG, Li CY. Expressions of osteopontin and vascular endothelial growth factor in brain glioma and their association with the prognosis. Chin J Neuromed. 2006;5:22–6.Google Scholar
  16. 16.
    Yue YY, Yi HQ. Expressions of osteopontin in patients with gliomas. J Pract Diag Treat. 2006;20:516–7.Google Scholar
  17. 17.
    Zeng T, Lin YF, Yang WZ. Expression of osteopontin in human brain gliomas and its clinical meanings. Chin J Clin Neurosurg. 2007;12:162–4.Google Scholar
  18. 18.
    Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398–405.CrossRefPubMedGoogle Scholar
  19. 19.
    Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res. 2008;14:293–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Du Q, Yu WH, Dong XQ. Expression of OPN and MMP-9 in human glioma in relation with its clinical significance. Zhejiang Med J. 2009;31:729–31.Google Scholar
  21. 21.
    Jiao BH. Expression and significance of OPN, MMP-9 and MVD in brain glioma. Master’s thesis. 2009;1–64.Google Scholar
  22. 22.
    Wang Y, Chen YH, Liu ZH, Wang RY, Jiao BH. Expression of MMP-9 and OPN in human glioma and their significance in the pathogenesis. J Brain Nerv Dis. 2012;20:128–32.Google Scholar
  23. 23.
    Erpolat OP, Gocun PU, Akmansu M, Ozgun G, Akyol G. Strahlenther O. Hypoxia-related molecules HIF-1α, CA9, and osteopontin: predictors of survival in patients with high-grade glioma. Strahlenther Onkol. 2013;189:147–54.Google Scholar
  24. 24.
    Papworth K, Bergh A, Grankvist K, Ljungberg B, Sandlund J, Rasmuson T. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma. Acta Oncol. 2013;52:159–65.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Mingfei Zhao
    • 1
  • Hangdi Xu
    • 2
  • Feng Liang
    • 1
  • Jiliang He
    • 3
  • Jianmin Zhang
    • 1
  1. 1.Department of Neurosurgery, Second Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Sir Run Run Shaw Hospital, School of MedicineZhejiang UniversityHangzhouChina
  3. 3.Institutes of Environmental Medicine, School of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations